Ensysce Biosciences (ENSC) Operating Expenses (2018 - 2025)

Ensysce Biosciences (ENSC) has reported Operating Expenses for 8 consecutive years, with $4.2 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Operating Expenses rose 52.63% year-over-year to $4.2 million in Q3 2025; TTM through Sep 2025 was $15.5 million, a 44.66% increase from a year earlier, with the FY2024 full-year figure at $11.9 million, down 7.79% from the prior year.
• Operating Expenses was $4.2 million for Q3 2025 at Ensysce Biosciences, up from $3.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $18.1 million in Q3 2021 and troughed at $774849.0 in Q1 2021.
• A 5-year average of $4.5 million and a median of $3.4 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 1367.66% in 2021 and sank 64.38% in 2022, its largest moves.
• Over 5 years, Operating Expenses stood at $3.6 million in 2021, then jumped by 109.61% to $7.6 million in 2022, then plunged by 51.92% to $3.7 million in 2023, then surged by 32.95% to $4.9 million in 2024, then dropped by 13.24% to $4.2 million in 2025.
• The last three Operating Expenses figures came in at $4.2 million (Q3 2025), $3.1 million (Q2 2025), and $3.3 million (Q1 2025), per Business Quant data.